The company’s first candidate drug is a conjugate in which the well-characterized chemotherapy agent methotrexate is attached to an engineered form of insulin growth factor (IGF). Our testing shows the IGF-methotrexate conjugate, even at 6-fold lower concentration, is more effective than unconjugated methotrexate against a prostate cancer model in animal models (http://www.ncbi.nlm.nih.gov/pubmed/19446281).
By targeting cancer cells which overexpress IGF-1 receptors and corresponding less exposure to healthy cells, we expect to observe reduced side effects compared to conventional chemotherapy.
- McTavish H, Griffin RJ, Terai K, Dudek AZ. 2009. Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone. Translational Research 153:275-82
- Peyrat JP, Bonneterre J. 1992. Type 1 IGF receptor in human breast diseases. Breast Cancer Research and Treatment 22:59-67.
- Stewart CE, Rotwein P. 1996. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol. Revs. 76:1005-1026.
- Papa, V. et al. 1990. J. Clin. Invest. 86:1503-1510.
- Jammes, H. et al. 1992. Br. J. Cancer 66:248-253
- Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R. 1995. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res. 55:3739-41.
- Surmacz, E. 2000. Function of the IGF-I receptor in breast cancer. J. Mammary Gland Biol. Neoplaisa 5:95-105.